Lynoo Pharmaceutical Packaging

Lynoo Pharmaceutical Packaging files for Hong Kong listing as core glass business weakens

Lynoo Pharmaceutical Packaging, a Chinese pharmaceutical glass packaging maker, has filed with the Hong Kong stock exchange for a dual A+H listing, with CMS International as one of two joint sponsors. In H1 2026 revenue rose 34.93% year on year to RMB 673m (USD 101m), driven by heat-resistant glassware, while net profit attributable to shareholders fell 23.95% to RMB 31.16m (USD 4.66m). Operating cash flow was negative, and the controlling shareholder has pledged 78.28% of its stake to guarantee borrowings of affiliated group companies.

Why this mattersFalling vial prices and volumes, negative operating cash flow and a 78% share pledge leave Lynoo's semiconductor-glass plan at the centre of its Hong Kong listing case.

• Lynoo Pharmaceutical Packaging filed a Hong Kong listing application for a dual A+H structure, with CMS International as one of two joint sponsors.
• H1 2026 revenue rose 34.93% year on year to RMB 673m (USD 101m), but net profit attributable to shareholders fell 23.95% to RMB 31.16m (USD 4.66m).
• Operating cash flow was negative RMB 68.3m (USD 10.2m) in H1 2026, after negative RMB 19.33m (USD 2.89m) in full-year 2025.
• The average selling price of tubular glass vials fell about 17% between 2023 and 2025, and volumes dropped 20.7% in 2025 to 3.199bn units.
• Controlling shareholder Lynoo Investment Holding has pledged 78.28% of its stake (20.16% of total share capital) to banks to guarantee borrowings of affiliated companies including Lynoo Group.
• IPO proceeds are earmarked for a 4.8m-units-a-year line for semiconductor packaging glass substrates; the pilot furnace was only ignited in June 2026.

Relevant to you? Yes No